US 10,889,807 B2
Lipolytic enzyme variants
Rene Marcel De Jong, Echt (NL); Chantal Christis, Echt (NL); and Neil Carr, Echt (NL)
Assigned to DSM IP ASSETS B.V., Heerlen (NL)
Appl. No. 16/471,121
Filed by DSM IP Assets B.V., Heerlen (NL)
PCT Filed Dec. 19, 2017, PCT No. PCT/EP2017/083526
§ 371(c)(1), (2) Date Jun. 19, 2019,
PCT Pub. No. WO2018/114940, PCT Pub. Date Jun. 28, 2018.
Claims priority of application No. 16205906 (EP), filed on Dec. 21, 2016; and application No. 17157061 (EP), filed on Feb. 21, 2017.
Prior Publication US 2019/0338261 A1, Nov. 7, 2019
Int. Cl. C12N 15/00 (2006.01); C12N 9/16 (2006.01); C12N 9/18 (2006.01); A21D 8/04 (2006.01); C12N 9/20 (2006.01)
CPC C12N 9/20 (2013.01) [A21D 8/042 (2013.01); C12Y 301/01003 (2013.01)] 19 Claims
 
1. A variant polypeptide having lipolytic activity, wherein the variant has an amino acid sequence which, when aligned with the amino acid sequence as set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid residue at a position corresponding to any of the positions 113, 122, 138, 141, 179, 282, 284, 286, 295, said positions being defined with reference to SEQ ID NO: 2,
and wherein said variant has at least 85% identity with the mature polypeptide as set out in SEQ ID NO: 2.